Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 23/10/2020

    CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 15/10/2020

    Pancreatic cancer: Subtypes with different aggressiveness discovered

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-subtypes-different-aggressiveness-discovered
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Press release - 05/10/2020

    Solar-battery effect enables a new light-driven organic microswimmer to operate in the dark

    An interdisciplinary team of scientists at the Max Planck Institutes for Intelligent Systems and Solid State Research has developed a biocompatible microswimmer made of carbon nitride, which they can propel forward through light. The particle can also store solar energy similar to miniature solar cells equipped with batteries, and can thus also swim in the dark using the stored energy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/solar-battery-effect-enables-new-light-driven-organic-microswimmer-operate-dark
  • Biochip systems - 02/09/2020 Hand hält einen Fett-Chip (Organ-on-a-Chip) in die Kamera. Gut zu sehen sind die Kammern und Kapillaren auf dem Mikrofluidik-System.

    Miniature organs with great potential

    Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…

    https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
  • Press release - 12/08/2020

    New technology provides insight into the development of immune cells

    The entire range of our blood and immune cells are derived from hematopoietic stem cells. Yet which genes influence how they develop into the different cell types? Scientists from the German Cancer Research Center (DKFZ) have now developed a new technology to answer this question.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-technology-provides-insight-development-immune-cells
  • Press release - 11/08/2020

    Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

    Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
  • Press release - 06/08/2020

    A bridge between artificial intelligence and the life sciences

    The great potential of artificial intelligence (AI) and machine learning for the life sciences – from basic research in biology to medical applications – has largely been neglected to date. A new research unit aims to support AI research in the life sciences and to forge international links with the activities in Heidelberg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-life-heidelberg-bridge-between-artificial-intelligence-and-life-sciences
  • Press release - 28/07/2020

    Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

    Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-start-european-clinical-phase-ii-trial-asunercept-covid-19-patients
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engagers" to fight cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
  • Press release - 13/05/2020

    Corona antibody tests from Reutlingen

    The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
  • Press release - 17/04/2020

    CoroNotes: New app supports medical studies on COVID-19

    Scientists from the Tübingen Competence Center for Machine Learning and physicians from the University Hospital of Tübingen have developed an app that uses anonymous health data to contribute to a better understanding of the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/coronotes-neue-app-unterstuetzt-medizinische-studien-zu-covid-19
  • Press release - 08/04/2020

    New Alliance in the Fight Against Coronavirus and COVID-19

    Scientists from Heidelberg and Mannheim launch research and development task force

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
  • Multiple sclerosis - 12/03/2020 Anatomie_des_menschlichen_Kopfes.jpg

    Direct application of biopharmaceuticals through the nose into the brain

    There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain
  • Press release - 03/03/2020

    CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

    Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Freiburg im Breisgau - 04/06/2019

    Spindiag’s continued road to success: Expansion of Series A with an additional 4 million euros for market entry

    Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiags-continued-road-to-success-expansion-of-series-a-with-an-additional-4-million-euros-for-market-entry
  • Expert interview - 13/05/2019 Telemedizin: Vitor Vieira (Inova DE) mit einem selbst entwickelten Wearable, einem T-Shirt zur verbesserten Interaktion zwischen Patienten und Kardiologen für fernkontrolliertes Monitoring

    Innovation management in the life sciences – Inova DE provides insights

    Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
  • Article - 16/04/2019 20190218_Foto_Labor_Quelle_UniversitNatsklinikum_Heidelberg.jpg

    Tumour monitoring using liquid biopsy

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
  • Expert interview on NTDs – part 1 - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Article - 03/04/2019 team.jpg

    HKK Bionics empowers hand gripping functions

    A spin-off from the Ulm University of Applied Sciences is aiming to provide people whose hands have been paralysed due to accident or illness with a new kind of orthopaedic aid. Dominik Hepp and Tobias Knobloch are currently starting serial production of a hand orthosis prototype. The two medical engineers from Ulm, who founded HKK Bionics GmbH in 2017, plan to commence final tests in 2019.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hkk-bionics-empowers-hand-gripping-functions
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Article - 24/01/2019 The photo shows an ultra filtration system.

    Scientists to combat antibiotic-resistant bacteria in wastewater

    In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

    https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater

Page 5 / 41

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 41
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search